Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

 SHIChang-cheng ¹ , TIANGang ² , LOUJiang ¹ , WUJing ³

1. Department of Pharmacy, the First People's Hospital of Hangzhou, Hangzhou 310006, China;
2. Zhejiang Chinese Medical University, Hangzhou 310053, China;
3. Department of Pharmacy, Hangzhou Obstetrics & Gynecology Hospital, Hangzhou 310008, China;

Corresponding author：

Keywords：

Selective serotonin reuptake inhibitors; Parkinson's disease; Depression; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20150073

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in the treatment of Parkinson's disease patients with depression. Methods The Cochrane Library (Issue 5, 2014), PubMed, EMbase, CNKI, VIP and WanFang Data databases were searched from inception to May 2014 for randomized controlled trials (RCTs) investigating the efficacy and safety of SSRIs for Parkinson's disease patients with depression. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. Results A total of 12 RCTs were included. The results of meta-analysis showed that the efficacy of SSRIs was better than placebo (RR=2.18, 95%CI 1.60 to 2.97, P<0.000 01) and the dropouts rates of SSRIs were higher than placebo (OR=3.02, 95%CI 1.04 to 8.79, P=0.04). However, the incidence rate of adverse events between the SSRIs group and the placebo group was not statistically different. Conclusion Current evidence indicates that SSRIs are effective for the Parkinson's disease patients with depression. Because of the limitation of quantity and quality of included studies, large-scale multi-center RCTs are required to confirm these findings.

Citation： SHIChang-cheng, TIANGang, LOUJiang, WUJing. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2015, 15(4): 439-444. doi: 10.7507/1672-2531.20150073 Copy

1.	Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 2008, 23(2):183-189.
2.	Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson's disease:systematic review and meta-analysis. J Psychopharmacol, 2013, 27(5):417-423.
3.	刘治军, 赵明, 陈乃宏, 等. 4种临床常见选择性5-羟色胺再摄取抑制剂对5-羟色胺转运体的抑制作用比较. 中国药学杂志, 2008, 43(15):1149-1152.
4.	Chen P, Kales HC, Weintraub D, et al. Antidepressant treatment of veterans with Parkinson's disease and depression:analysis of a national sample. J Geriatr Psychiatry Neurol, 2007, 20(3):161-165.
5.	de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson's disease. Neurology, 1997, 48(5):1277-1281.
6.	全国椎体系疾病讨论会. 帕金森病及帕金森综合症的诊断标准和鉴别诊断. 中华神经精神科杂志, 1985, 18(4):256.
7.	邓可刚. 循证医学证据的检索步骤与检索系统的选择. 中国循证医学杂志, 2004, 4(9):634-637.
8.	Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:Assessing risk of bias in included studies. In:Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
9.	陈娟, 李强. 氟西汀治疗帕金森病抑郁患者的疗效观察. 中国实用神经疾病杂志, 2009, 12(15):28-29.
10.	Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in parkinson's disease:a double-blind, randomized, placebo-controlled study. Mov Disord, 2008, 23(6):850-857.
11.	冯传学, 王启盛. 氟西汀对帕金森病伴抑郁及神经症状的影响. 中国现代药物应用, 2008, 2(20):55-56.
12.	Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry, 2003, 18(6):552-554.
13.	林勇, 丁雪萍, 周勇. 舍曲林治疗帕金森病合并抑郁的疗效分析. 精神医学杂志, 2007, 20(6):389-390.
14.	林智君, 郑选梅. 百忧解治疗帕金森病伴抑郁的临床研究. 中国实用医药, 2010, 5(12):80-81.
15.	刘晶晶, 王恩铭, 江振华, 等. 帕罗西汀治疗帕金森病抑郁患者的疗效. 实用临床医学, 2013, 14(1):19-25.
16.	马海蓉. 帕罗西汀治疗帕金森病伴抑郁的疗效评价. 中国现代应用药学杂志, 2006, 23(4):344-345.
17.	孟新玲, 房江山, 刘远新, 等. 盐酸帕罗西汀片对帕金森病患者合并抑郁和焦虑症状的临床疗效. 中国临床药理学杂志, 2013, 29(6):403-405.
18.	Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, 72(10):886-892.
19.	Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, 78(16):1229-1236.
20.	张春颖, 林传水, 贺国凤. 帕罗西汀对帕金森病伴抑郁及神经症状的影响. 神经疾病与精神卫生, 2005, 5(3):208-209.

1. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 2008, 23(2):183-189.
2. Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson's disease:systematic review and meta-analysis. J Psychopharmacol, 2013, 27(5):417-423.
3. 刘治军, 赵明, 陈乃宏, 等. 4种临床常见选择性5-羟色胺再摄取抑制剂对5-羟色胺转运体的抑制作用比较. 中国药学杂志, 2008, 43(15):1149-1152.
4. Chen P, Kales HC, Weintraub D, et al. Antidepressant treatment of veterans with Parkinson's disease and depression:analysis of a national sample. J Geriatr Psychiatry Neurol, 2007, 20(3):161-165.
5. de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson's disease. Neurology, 1997, 48(5):1277-1281.
6. 全国椎体系疾病讨论会. 帕金森病及帕金森综合症的诊断标准和鉴别诊断. 中华神经精神科杂志, 1985, 18(4):256.
7. 邓可刚. 循证医学证据的检索步骤与检索系统的选择. 中国循证医学杂志, 2004, 4(9):634-637.
8. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:Assessing risk of bias in included studies. In:Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at:www.cochrane-handbook.org.
9. 陈娟, 李强. 氟西汀治疗帕金森病抑郁患者的疗效观察. 中国实用神经疾病杂志, 2009, 12(15):28-29.
10. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in parkinson's disease:a double-blind, randomized, placebo-controlled study. Mov Disord, 2008, 23(6):850-857.
11. 冯传学, 王启盛. 氟西汀对帕金森病伴抑郁及神经症状的影响. 中国现代药物应用, 2008, 2(20):55-56.
12. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry, 2003, 18(6):552-554.
13. 林勇, 丁雪萍, 周勇. 舍曲林治疗帕金森病合并抑郁的疗效分析. 精神医学杂志, 2007, 20(6):389-390.
14. 林智君, 郑选梅. 百忧解治疗帕金森病伴抑郁的临床研究. 中国实用医药, 2010, 5(12):80-81.
15. 刘晶晶, 王恩铭, 江振华, 等. 帕罗西汀治疗帕金森病抑郁患者的疗效. 实用临床医学, 2013, 14(1):19-25.
16. 马海蓉. 帕罗西汀治疗帕金森病伴抑郁的疗效评价. 中国现代应用药学杂志, 2006, 23(4):344-345.
17. 孟新玲, 房江山, 刘远新, 等. 盐酸帕罗西汀片对帕金森病患者合并抑郁和焦虑症状的临床疗效. 中国临床药理学杂志, 2013, 29(6):403-405.
18. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, 72(10):886-892.
19. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, 78(16):1229-1236.
20. 张春颖, 林传水, 贺国凤. 帕罗西汀对帕金森病伴抑郁及神经症状的影响. 神经疾病与精神卫生, 2005, 5(3):208-209.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for Parkinson's Disease Patients with Depression: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content